Spots Global Cancer Trial Database for Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Official Title: Efficacy and Safety of Serplulimab, Lenvatinib, and Paclitaxel in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After First-line Immunotherapy: a Prospective, Single-armed Clinical Trial
Study ID: NCT05585580
Study Description
Brief Summary: This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab, Lenvatinib and Paclitaxel in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after first-line immunotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Qilu hospital of Shandong univertisy, Jinan, Shandong, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Qingdao Municipal Hospital（Group）, Qingdao, Shandong, China
Yantai Yuhuangding Hospital, Yantai, Shandong, China
Linyi Cancer Hospital, Linyi, , China
Contact Details
Name: Lian Liu
Affiliation: Qilu hospital of Shandong univertisy
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
